Wall Street Zen Downgrades Ocugen to 'Sell' Rating

The biopharmaceutical company faces challenges as analysts lower their outlook.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Ocugen (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on gene therapies and vaccines, has been downgraded from a 'hold' to a 'sell' rating by analysts at Wall Street Zen. This comes after the company reported quarterly earnings and revenue that missed analyst estimates.

Why it matters

The downgrade highlights the ongoing challenges Ocugen faces as it works to develop its pipeline of gene therapies and vaccines. As a smaller biotech firm, Ocugen relies heavily on investor confidence, so a 'sell' rating from a prominent analyst could impact the company's stock price and ability to raise future funding.

The details

In its report, Wall Street Zen cited Ocugen's disappointing financial results and the competitive landscape in the gene therapy and vaccine markets as reasons for the downgrade. The analysts also noted that Ocugen has received mixed ratings from other research firms, with some maintaining a 'buy' recommendation while others have issued 'sell' ratings.

  • Ocugen reported its quarterly earnings on March 4, 2026.
  • Wall Street Zen issued its downgrade report on March 9, 2026.

The players

Ocugen

A clinical-stage biopharmaceutical company focused on developing gene therapies for rare inherited retinal diseases and vaccines for infectious diseases. Headquartered in Malvern, Pennsylvania.

Wall Street Zen

A stock research and analysis firm that provides ratings and recommendations to investors.

Got photos? Submit your photos here. ›

What’s next

Ocugen will need to demonstrate progress in its clinical trials and secure additional funding to regain investor confidence and potentially reverse the 'sell' rating from Wall Street Zen.

The takeaway

The downgrade of Ocugen by Wall Street Zen underscores the difficulties smaller biotech firms face in navigating the competitive landscape and meeting investor expectations. Ocugen will need to focus on executing its development plans and communicating its progress effectively to regain a more favorable rating from analysts.